Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Chief Scientific Officer | March 01, 2025 | March 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date March 01, 2025 · Filed March 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 265,662 |
Ending reported balance
After 2025-03-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-03-01 · Exercise / conversion · Acquired 50,000 · Balance 281,995 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Row 2 · 2025-03-01 · Exercise / conversion · Acquired 10,925 · Balance 292,920 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Row 3 · 2025-03-01 · Tax withholding · Disposed 27,258 · Balance 265,662 F2: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-01 · Exercise / conversion · Disposed 50,000 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,925 |
Reported balance
After 2025-03-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-03-01 · Exercise / conversion · Disposed 10,925 · Balance 10,925 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 193 |
Reported balance
Holding disclosure · report date 2025-03-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 193 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
F4: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2025 Filed Mar 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 10,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006495 · form4-03042025_040310.xml · derivative · entry 6 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,925 Underlying: Common Stock · 10,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006495 · form4-03042025_040310.xml · derivative · entry 5 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 27,258 | $1.99 | $54,243.42 |
DisclosureSEC source: 0001415889-25-006495 · form4-03042025_040310.xml · nonDerivative · entry 3 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,662 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 10,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-006495 · form4-03042025_040310.xml · nonDerivative · entry 2 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-006495 · form4-03042025_040310.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 293,500 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-25-002940 · form4-02042025_040206.xml · derivative · entry 8 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,500 Underlying: Common Stock · 293,500 shares Expires 2035-02-02 F6 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 83,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002940 · form4-02042025_040206.xml · derivative · entry 7 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,900 Underlying: Common Stock · 83,900 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 14,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002940 · form4-02042025_040206.xml · derivative · entry 6 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,250 Underlying: Common Stock · 14,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002940 · form4-02042025_040206.xml · derivative · entry 5 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 11,317 | $2.48 | $28,066.16 |
DisclosureSEC source: 0001415889-25-002940 · form4-02042025_040206.xml · nonDerivative · entry 3 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,995 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 14,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002940 · form4-02042025_040206.xml · nonDerivative · entry 2 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002940 · form4-02042025_040206.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 17,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000624 · form4-01032025_060109.xml · derivative · entry 8 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,287 Underlying: Common Stock · 17,380 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 52,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000624 · form4-01032025_060109.xml · derivative · entry 7 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,667 Underlying: Common Stock · 52,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 8,914 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000624 · form4-01032025_060109.xml · nonDerivative · entry 4 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,062 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 17,380 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000624 · form4-01032025_060109.xml · nonDerivative · entry 3 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 73,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000624 · form4-01032025_060109.xml · derivative · entry 6 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,750 Underlying: Common Stock · 73,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: 50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F3 · derivative.expiration_date: 50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 32,937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000624 · form4-01032025_060109.xml · nonDerivative · entry 2 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,596 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 73,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000624 · form4-01032025_060109.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GiftCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029092 · form4-12122024_041201.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,783 Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 17:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004402 · doc4.xml · derivative · entry 10 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 17:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 3,531 | $1.24 | $4,378.44 |
DisclosureSEC source: 0001209191-24-004402 · doc4.xml · nonDerivative · entry 6 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,783 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 17:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-004402 · doc4.xml · nonDerivative · entry 5 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 17:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 10,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004402 · doc4.xml · derivative · entry 9 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,850 Underlying: Common Stock · 10,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 17:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004402 · doc4.xml · derivative · entry 8 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 17:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 3,183 | $1.24 | $3,946.92 |
DisclosureSEC source: 0001209191-24-004402 · doc4.xml · nonDerivative · entry 4 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,814 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 17:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 10,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-004402 · doc4.xml · nonDerivative · entry 3 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 17:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 14,569 | $1.24 | $18,065.56 |
DisclosureSEC source: 0001209191-24-004402 · doc4.xml · nonDerivative · entry 2 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,072 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 17:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-004402 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:31 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 147,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002840 · doc4.xml · derivative · entry 7 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,500 Underlying: Common Stock · 147,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: 50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F6 · derivative.expiration_date: 50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:31 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 59,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002840 · doc4.xml · derivative · entry 6 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:31 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 206,500 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-24-002840 · doc4.xml · derivative · entry 5 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,500 Underlying: Common Stock · 206,500 shares Expires 2034-01-31 F4 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:31 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Unit · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002840 · doc4.xml · derivative · entry 4 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:31 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,583 | $1.20 | $3,099.60 |
DisclosureSEC source: 0001209191-24-002840 · doc4.xml · nonDerivative · entry 2 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,641 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:31 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-002840 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| October 23, 2023 Filed Oct 25, 2023 16:28 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 6,000 | $5.08 | $30,460.20 |
DisclosureSEC source: 0001209191-23-053558 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,724 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2023. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 21, 2023 Filed Aug 22, 2023 16:31 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 6,000 | $7.32 | $43,894.80 |
DisclosureSEC source: 0001209191-23-046905 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,724 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2023. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.18 to $7.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 16:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 6,000 | $10.28 | $61,662.60 |
DisclosureSEC source: 0001209191-23-039070 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,724 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2023. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $9.84 to $10.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2023 Filed Mar 3, 2023 20:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 16,037 | $12.63 | $202,614.67 |
DisclosureSEC source: 0001209191-23-016065 · doc4.xml · nonDerivative · entry 6 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,724 F4 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.43 to $12.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 20:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016065 · doc4.xml · derivative · entry 11 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F9 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 20:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016065 · doc4.xml · nonDerivative · entry 5 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 20:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 14,800 | $12.37 | $183,024.20 |
DisclosureSEC source: 0001209191-23-016065 · doc4.xml · nonDerivative · entry 4 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,261 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.90 to $12.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 10,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016065 · doc4.xml · derivative · entry 10 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,775 Underlying: Common Stock · 10,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F8 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. F8 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016065 · doc4.xml · derivative · entry 9 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F7 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F7 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016065 · doc4.xml · derivative · entry 8 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 10,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016065 · doc4.xml · nonDerivative · entry 3 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016065 · doc4.xml · nonDerivative · entry 2 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 13,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016065 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:34 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 5,000 | $13.06 | $65,310.50 |
DisclosureSEC source: 0001209191-23-010658 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,386 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.79 to $13.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:07 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007023 · doc4.xml · derivative · entry 2 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.